Abstract | BACKGROUND: OBJECTIVE: The aim of this open study is to describe the change in serum CEA in eight patients with advanced colorectal metastatic disease treated with Marimastat. RESULTS: The mean percentage change in serum CEA level of the patients before commencing Marimastat treatment was 35.6 (SD 25.7) with a mean percentage change in serum CEA of 6.8 (SD 18.3) during the first month of treatment. The average percentage change in serum CEA after one month of treatment with Marimastat was 20 percent. CONCLUSIONS: Although the study sample is small, there is a significant difference in serum CEA change prior to and post commencement of marimastat treatment. It is important to note that the observation period was short for most patients due to their advanced disease.
|
Authors | H North, J King, D L Morris |
Journal | International journal of surgical investigation
(Int J Surg Investig)
Vol. 2
Issue 3
Pg. 213-7
( 2000)
ISSN: 1028-5229 [Print] Switzerland |
PMID | 12678521
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Carcinoembryonic Antigen
- Enzyme Inhibitors
- Hydroxamic Acids
- marimastat
|
Topics |
- Adult
- Aged
- Carcinoembryonic Antigen
(blood)
- Colorectal Neoplasms
(blood, drug therapy, pathology)
- Enzyme Inhibitors
(therapeutic use)
- Female
- Humans
- Hydroxamic Acids
(therapeutic use)
- Liver Neoplasms
(secondary)
- Lung Neoplasms
(secondary)
- Male
- Middle Aged
- Neoplasm Metastasis
- Treatment Outcome
|